Small Molecules Targeting Prostate Cancer

Veru Pharma is dedicated to developing innovative treatments for significant health issues, particularly focusing on high-quality weight loss, breast cancer, and viral-related acute respiratory distress syndrome (ARDS). One of their key technologies is enobosarm, a novel oral selective androgen receptor modulator (SARM) designed to mitigate muscle loss in patients undergoing weight loss therapy with glucagon-like peptide-1 (GLP-1) drugs. This technology aims to enhance the weight loss process while preserving muscle mass, addressing a critical concern for patients, especially older adults who may experience sarcopenic obesity. Enobosarm has shown promise in clinical trials, demonstrating its potential to increase muscle mass and improve physical function while reducing fat mass.

In addition to enobosarm, Veru is also developing sabizabulin, a microtubule disruptor intended for the treatment of hospitalized patients with viral-induced ARDS. The company’s pipeline reflects a commitment to addressing unmet medical needs through advanced biopharmaceutical research. Veru's approach combines rigorous clinical testing with a focus on patient outcomes, as evidenced by their ongoing Phase 2b clinical trials for enobosarm, which aim to evaluate its efficacy in preserving muscle and augmenting fat loss in at-risk populations. Overall, Veru Pharma's technologies represent a significant advancement in the treatment of metabolic diseases and oncology, with a strong emphasis on improving the quality of life for patients.

United States

Veru is an oncology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer and breast cancers. Our strategy is primarily to focus on the clinical development and commercialization of oncology drugs for the management of two of the most prevalent cancers globally – prostate cancer and breast cancer.

Cancer

Endocrine System Diseases

Infectious Diseases

Metabolic Diseases

Veru Pharma

Benign prostatic hyperplasia

TADFIN™ combination of a PDE5 inhibitor and 5 alpha reductase inhibitor for the treatment of enlarged prostate (BPH)

ENTADFI™ (tadalafil and finasteride)

ER+/HER2- breast cancer

HER2-expressing cancers

Enobosarm, selective androgen receptor targeting agonist, for the treatment of estrogen receptor positive (ER+) and human epidermal growth factor receptor 2 (HER2-) metastatic breast cancer.

Enobosarm +/- abemaciclib

COVID-19

Sabizabulin is a cytoskeleton disruptor which by causing microtubule depolymerization has both anti-viral and anti-inflammatory activity and could be effective against the SARS-CoV-2 virus by disrupting its intracellular transport along the microtubules. Microtubule trafficking is critical for viruses to be transported, replicated, assembled, and released from the cell. In addition, microtubule depolymerization drugs that target the “colchicine binding site” of microtubules, like sabizabulin, also have strong anti-inflammatory effects, including the potential to treat the cytokine release syndrome (cytokine storm) and septic shock induced by the SARS-CoV-2 viral infection that is associated with high COVID-19 mortality rates.

Sabizabulin (Veru-111)

Obesity

Enobosarm +GLP-1 drugs [Ozempic® + Wegovy® + Mounjaro®]

Prostate cancer

VERU-100 is a novel, proprietary peptide formulation designed with multiple beneficial clinical attributes addressing the shortfalls of the current multi-billion-dollar androgen deprivation therapy market for advanced prostate cancer.

VERU-100

Castration-resistant prostate cancer

VERU-111 is an oral cytoskeletal disruptor that disrupts microtubules supporting the cytoskeleton and has no affinity for multidrug resistance proteins. &nbsp;VERU-111 is a novel oral selective antitubulin that targets alpha and beta tubulin for metastatic prostate cancer as well as for other forms of advanced cancers.&nbsp;
<a href="https://meetinglibrary.asco.org/record/198061/abstract">source</a>

Sabizabulin (VERU-111)

Triple-negative breast cancer

VERU-111, an oral, first-in-class alpha and beta tubulin inhibitor/cytoskeleton disruptor small molecule, for the treatment of taxane resistant metastatic triple negative breast cancer.

Sabizabulin (VERU-111) + Enobosarm

Hot flashes

Estrogen receptor agonist for the treatment of hot flashes caused by prostate cancer hormonal therapies in men with advanced prostate cancer.

Veru Pharma

Company Details